We used GDSC, the largest publicly available pharmacogenomics database, to predict the sensitivity of G2M checkpoint inhibitor drugs in high and low ATG5 expression HNSCC samples, which based on sample transcriptomes. This evidence concerns the gene ATG5 and head and neck squamous cell carcinoma.